Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cautious start for Europe

Mon, 19th Jun 2023 09:13

STOXX 600 down 0.6%

*

All major indices in the red

*

Wall Street futures flat

*

U.S. markets closed for Juneteenth holiday

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

CAUTIOUS START FOR EUROPE (0811 GMT)

European equity markets are taking a breather on Monday after a strong performance last week that saw Germany's DAX close at a record high and broader European shares notch their biggest weekly gain in two months.

The pan-European benchmark STOXX 600 index is down around 0.6%, while the DAX , CAC 40 and FTSE 100 are down 0.3%-0.6%.

"Investors are lacking Monday motivation today, as caution returns amid worries about global growth," says Susannah Streeter, head of money and markets, Hargreaves Lansdown.

"European indices have opened lower ... as investors mull what's ahead for the path of interest rates, given the stubbornness of inflation, while concerns persist about China's recovery losing steam."

Shares in Franco-German lab supplies maker Sartorius are down around 13% after the company cut its margin and sales forecast.

Aerospace and Defence stocks are a rare bright spot, as attention falls on Paris, where the world's largest aviation trade show is kicking off, with airlines going into the event with growing demand expectations.

Here's your opening snapshot:

(Samuel Indyk)

MONDAY BLUES FOR EUROPEAN FUTURES (0635 GMT)

European equity futures are struggling on Monday, consolidating after major indices clocked their biggest weekly gain in two months last week.

Euro STOXX 50 futures are down 0.6%. Futures on Germany's DAX are also losing 0.6% after the index closed at a

record high

on Friday.

With a U.S. market holiday and a lack of major data releases in Europe, focus is falling on geopolitics as U.S. Secretary of State Antony Blinken wraps up his

trip to China

, where a meeting with Chinese President Xi Jinping might be in the offing.

In company news, AstraZeneca will be in focus after the Financial Times reported the drugmaker is drafting a plan to

spin off its China business.

Attention will also be on aerospace and defence names, as the week-long Paris Airshow kicks off.

(Samuel Indyk)

READY FOR MORE RATE HIKES, AND ONE CUT (0554 GMT)

It's been predictably subdued in Asia as a U.S. holiday provides a convenient excuse for stocks to consolidate recent hefty gains before a bevy of central bank meetings this week. Most indices are down, with the Nikkei off modestly having climbed 22% over a 10-week streak to hit 33-year highs.

S&P 500 futures were also flat having risen for five weeks in a row, while the NASDAQ has notched eight weeks of gains. Those rallies are narrowly based, though, with just nine large-cap stocks making up 30% of the S&P 500. It's hard to call the index a "diversified" investment any more.

Markets are watching U.S. Secretary of State Antony Blinken's visit to Beijing, though you know expectations are low when it's newsworthy that a Chinese diplomat deigned to shake his hand.

Among currencies, the yen downtrend remains alive and well as the euro and dollar both make new highs, albeit by just a few ticks. Further losses look likely unless and until the Bank of Japan takes another step toward tightening, which many Western analysts see as possible in July. Governor Kazuo Ueda, however, seemed to set a high bar for a move last week by saying his outlook for inflation would have to shift "sharply" to justify a move.

The coming week is also jammed with central bank action, led by China on Tuesday where prime loan rates are expected to be cut by 10 basis points. That might be pushing on string given mortgage rates have already fallen markedly and lower rates only eat into the return on household savings. Markets are really hanging on for more fiscal stimulus to revive growth, as it has so often in the past.

Federal Reserve Chair Jerome Powell appears before lawmakers on Wednesday and Thursday and may again try to convince markets that two more quarter-point rate hikes are really, honestly, cross-my-heart likely.

Futures seem unimpressed with just 21 basis points of tightening priced in by September, though one final hike in July is rated as a decent 70% chance.

In contrast, markets are baying for the Bank of England to hike when it meets on Thursday, the only question being by 25 or 50 basis points. Futures lean toward the smaller move to 4.75% but also have rates rising to at least 5.75% given stubborn inflation and surging wages.

Gilt yields have already hit 15-year highs, causing havoc in the UK mortgage market and lifting the government's already astronomical borrowing costs.

Rate hikes are also expected in Norway and Switzerland this week, perhaps by 50 basis points, though that will likely pale in comparison to Turkey's central bank as some analysts see rates rising from the current 8% to as much as 25%.

Key developments that could influence markets on Monday:

- ECB board member Isabel Schnabel, ECB Vice President Luis de Guindos and ECB chief economist Philip Lane are all speaking

- U.S. stock and bond markets are closed, while the NAHB housing market index for June is due

(Wayne Cole)

More News
27 Jun 2024 13:00

German vaccine panel endorses Astra-Sanofi's RSV shot for infants

FRANKFURT, June 27 (Reuters) - Germany's influential vaccine advisory panel said on Thursday all infants in the country should receive AstraZeneca and Sanofi's antibody therapy to protect them against the common respiratory infection RSV.

Read more
26 Jun 2024 08:40

TOP NEWS: AstraZeneca's Tagrisso plus chemo gets approval in China

(Alliance News) - AstraZeneca PLC on Wednesday celebrated the approval of Tagrisso plus chemotherapy for a cancer form in China, a day after a similar approval in Japan.

Read more
25 Jun 2024 09:05

TOP NEWS: AstraZeneca details mixed findings from cancer drug trials

(Alliance News) - AstraZeneca PLC on Tuesday announced a mixed bag of results for two of its leading cancer drugs Imfinzi and Tagrisso.

Read more
25 Jun 2024 07:48

LONDON BRIEFING: Mixed bag for Astra drug; Landsec ups Bluewater stake

(Alliance News) - London's FTSE 100 is set to tread water on Tuesday, with a slump for US tech shares overnight keeping a lid on enthusiasm.

Read more
25 Jun 2024 07:17

AstraZeneca posts mixed results from recent Imfinzi trials

(Sharecast News) - AstraZeneca announced contrasting results from two phase three trials involving its immunotherapy drug 'Imfinzi', or durvalumab, on Tuesday.

Read more
24 Jun 2024 15:40

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave a boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
24 Jun 2024 14:56

US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit

WASHINGTON, June 24 (Reuters) - The U.S. Supreme Court gave boost on Monday to a challenge by 21 pharmaceutical and medical equipment companies led by AstraZeneca to a lawsuit accusing them of illegally helping to fund terrorism that killed or injured hundreds of American troops and civilians in Iraq.

Read more
20 Jun 2024 10:56

TOP NEWS: AstraZeneca's Truqap gets OK from EU for breast cancer form

(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslodex, for the treatment of a form of breast cancer.

Read more
18 Jun 2024 09:33

TOP NEWS: AstraZeneca disappointed by breast cancer drug trial results

(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.

Read more
18 Jun 2024 07:51

LONDON BRIEFING: Ashtead profit declines; Whitbread sales rise

(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with inflation data and central bank decisions the key plot points as the week progresses.

Read more
18 Jun 2024 07:17

AstraZeneca trial fails to treat 'challenging' breast cancer

(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with paclitaxel did not achieve its primary endpoints.

Read more
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.